CGTX vs BARK Comparison

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

BARK Inc believe that dogs and humans are good together and it aspire to be the world's favorite dog brand. It is a team of dog-obsessed people committed to delivering personalization at scale by satisfying each dog's distinct personality, preferences, and needs with the products and services. It is an omnichannel brand that designs and develops proprietary products for dogs across two key brands: BarkBox and Super Chewer. All of its products are designed and developed in-house, and are BARK branded. Its segments are DTC, and Commerce. It generates majority of revenue from DTC. Direct to Consumer generates revenue from subscription products that feature monthly themes of premium quality BarkBox and Super Chewer toys and BARK-branded treats and chews.